{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":false},"limitationsAndCaveats":{"description":"Study accrual has been lower (i.e., 26 total) than the planned target accrual of 50 due to the prioritization of other clinical trials using an alternative radiometal (yttrium-90 \\[90Y\\]) and antibody construct (BC8-DOTA)."},"pointOfContact":{"email":"jorozco@fredhutch.org","organization":"Fred Hutchinson Cancer Center","phone":"(206) 667-4102","title":"Johnnie Orozco, MD, PhD"}}